Advertisement
U.S. markets close in 3 hours 17 minutes

Theravance Biopharma, Inc. (TBPH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
8.90-0.11 (-1.22%)
As of 12:43PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close9.01
Open9.00
Bid8.86 x 100
Ask8.92 x 100
Day's Range8.77 - 9.00
52 Week Range8.21 - 12.03
Volume91,943
Avg. Volume366,513
Market Cap428.666M
Beta (5Y Monthly)0.37
PE Ratio (TTM)N/A
EPS (TTM)-1.00
Earnings DateMay 06, 2024 - May 10, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TBPH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Theravance Biopharma, Inc.
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    18 hours agoMorningstar
View more
  • Zacks

    Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?

    Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • InvestorPlace

    Short-Squeeze Showdown: 3 Stocks Ready to Crush the Skeptics

    The life of a bearish speculator can be dangerous and that’s part of the appeal of short-squeeze stocks: you can make life miserable for those attempting to cynically extract profits from others’ misery. At the most elemental level, I suppose it’s like watching a lion eating a safari hunter. Perhaps it’s a bit irrational but I believe I speak for most of us: we’d root for the lion and feel that the hunter received poetic justice. It’s what the kids call fool around and find out or FAFO. And that

  • Insider Monkey

    Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript

    Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Call Transcript February 26, 2024 Theravance Biopharma, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.04. TBPH isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, good afternoon. I’d […]